Stocks and Investing Stocks and Investing
Tue, November 17, 2020
Mon, November 16, 2020

Danielle Brill Upgraded (ACAD) to Strong Buy and Held Target at $65 on, Nov 16th, 2020


Published on 2024-10-27 14:47:14 - WOPRAI, Danielle Brill
  Print publication without navigation


Danielle Brill of Raymond James, Upgraded "ACADIA Pharmaceuticals Inc." (ACAD) to Strong Buy and Held Target at $65 on, Nov 16th, 2020.

Danielle has made no other calls on ACAD in the last 4 months.



There are 6 other peers that have a rating on ACAD. Out of the 6 peers that are also analyzing ACAD, 1 agrees with Danielle's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Jay Olson of "Oppenheimer" Maintained at Hold with Decreased Target to $42 on, Tuesday, July 21st, 2020


These are the ratings of the 5 analyists that currently disagree with Danielle


  • Jeffrey Hung of "Morgan Stanley" Maintained at Buy with Increased Target to $58 on, Thursday, November 5th, 2020
  • Marc Goodman of "SVB Leerink" Maintained at Buy with Decreased Target to $52 on, Thursday, August 6th, 2020
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $60 on, Thursday, August 6th, 2020
  • Charles Duncan of "Cantor Fitzgerald" Maintained at Buy with Decreased Target to $61 on, Tuesday, July 21st, 2020
  • Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $55 on, Tuesday, July 21st, 2020
Contributing Sources